Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
February 08, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate...
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
January 08, 2018 16:41 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
November 02, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30,...
FDA Recognizes Orphan Drug Exclusivity for Adamas’ GOCOVRI™
October 25, 2017 12:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Drug Products...